Britain’s medicines regulator has approved a novel antibiotic developed by Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company based in San Diego, California.
Rezzayo (rezafungin acetate) is a novel once-weekly echinocandin, developed for use against candidemia and invasive candidiasis in adults.
The decision from the Medicines and Healthcare products Regulatory Agency (MHRA) was made based on positive results from the Phase III ReSTORE trial, which showed non-inferiority over the standard of care, daily caspofungin.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze